SD-doxycycline were less likely to have new-onset GID within 1 year of starting treatment relative to patients who were taking CD-doxycycline (1-year cumulative incidence of GID of 8.3% and 12.0% for patients started on SD-doxycycline and CD-doxycycline, respectively; aOR ¼ 0.68 [95% CI ¼ 0.61-0.75]; P \.0001).
As a cross-sectional study using claims database data, our inferences were limited to association but not causation. We were unable to determine the medication frequency and duration, nor could we concretely identify the reason for treatment. Severity was not accounted for in the analysis. The presence of antibiotic intake in the population may act as a marker for rosacea severity, which has been associated with higher GID prevalence. 1 In addition, few patients prescribed SD-doxycycline were doxycycline-na€ ıve. However, various adjusted analyses showed a persistent association with CD-doxycycline and increased GID prevalence, and a generally null association with SD-doxycycline and GID prevalence.
Rosacea patients prescribed SD-doxycycline had fewer overall GIDs than those taking CD-doxycycline; in addition, no significant difference was seen in GID prevalence between SD and no doxycycline. These data suggest that CDdoxycycline usage may contribute to the previously reported association between rosacea and GID. This may partly be caused by a dose-dependent effect, but aOR, Adjusted odds ratio; CD, conventional dose; CI, confidence interval; SD, subantimicrobial dose, modified release. *Rosacea population 30 to 64 years of age with standard dose (50 or 100 mg), CD-doxycycline intake and without SD-doxycycline intake. This is less than the sum of the 50 and 100 mg CD-doxycycline groups combined due to the overlap of individuals taking both doses. y Rosacea population 30 to 64 years of age without CD-doxycycline intake and without SD-doxycycline intake. z Adjusted odds ratios (aOR) were computed using logistic regression, adjusting for age and sex.
x Rosacea population 30 to 64 years of age with SD-doxycycline intake. { Rosacea population 30 to 64 years of age with CD-doxycycline 100 mg intake. k Rosacea population 30 to 64 years of age with CD-doxycycline 50 mg intake.
Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy
To the Editor: Effective systemic therapies have improved survival in advanced melanoma, resulting in a higher lifetime risk for brain metastases. 1 Male sex, truncal or head and neck location, and thick or ulcerated primary lesions are well-accepted risk factors. 2 Histologic subtype, however, has not been extensively studied. We report 1 of the largest series of melanoma brain metastases (MBMs) to better define clinicopathologic risk factors and guide management and surveillance decisions.
An institutional melanoma database review identified 3756 patients in whom metastatic melanoma had been diagnosed between diagnosed 1971 and 2013. Patients were divided into 2 groups on the basis of whether they developed MBMs. Primary end points were development of MBMs and 2-year MBM-free survival (MBMFS). The secondary end point was overall survival (OS).
Of the 2132 patients included in the final analysis, 397 (18.6%) developed brain metastases. Univariable analysis identified sex, primary location, ulceration, and histologic subtype as predictors of 2-year MBMFS in patients who developed stage IV disease (Fig 1) . Multivariable analyses demonstrated that axial location (P \ .01), presence of ulceration (P ¼ .04), and desmoplastic (P ¼ .02) and nodular (P ¼ .03) histologic variants were associated with a higher risk for development of MBMs. The presence 
